Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.

PURPOSE To study the kinetics of polylactide (PLA) nanoparticle (NP) localization within the intraocular tissues and to evaluate their potential to release encapsulated material. METHODS A single intravitreous injection (5 micro L) of an NP suspension (2.2 mg/mL) encapsulating either Rh-6G (Rh) or Nile red (Nr) was performed. Animals were killed at various times, and the NPs localization within the intraocular tissues was studied by environmental scanning electron microscopy (ESEM), confocal microscopy, light microscopy histology, fluorescence microscopy, and immunohistochemistry. Eyes injected with blank NPs, free Rh, or PBS solution were used as the control. RESULTS ESEM showed the flow of the NPs from the site of injection into the vitreous cavity and their rapid settling on the internal limiting membrane. Histology demonstrated the anatomic integrity of the injected eyes and showed no toxic effects. A mild inflammatory cell infiltrate was observed in the ciliary body 6 hours after the injection and in the posterior vitreous and retina at 18 to 24 hours. The intensity of inflammation decreased markedly by 48 hours. Confocal and fluorescence microscopy and immunohistochemistry showed that a transretinal movement of the NPs was gradually taking place with a later localization in the RPE cells. Rh encapsulated within the injected NPs diffused and stained the retina and RPE cells. PLA NPs were still present within the RPE cells 4 months after a single intravitreous injection. CONCLUSIONS Intravitreous injection of PLA NPs appears to result in transretinal movement, with a preferential localization in the RPE cells. Encapsulated Rh diffuses from the NPs and stains the neuroretina and the RPE cells. The findings support the idea that specific targeting of these tissues is feasible. Furthermore, the presence of the NPs within the RPE cells 4 months after a single injection shows that a steady and continuous delivery of drugs can be achieved.

[1]  Y. Ikada,et al.  Toxicity test of biodegradable polymers by implantation in rabbit cornea. , 1992, Journal of biomedical materials research.

[2]  C Vigneron,et al.  Protein C-loaded monomethoxypoly (ethylene oxide)-poly(lactic acid) nanoparticles. , 2001, International journal of pharmaceutics.

[3]  J. Feijen,et al.  Formulation and Lyoprotection of Poly(Lactic Acid-Co-Ethylene Oxide) Nanoparticles: Influence on Physical Stability and In Vitro Cell Uptake , 1999, Pharmaceutical Research.

[4]  J. Robinson,et al.  Study of the mechanism of interaction of poly(ϵ-caprolactone) nanocapsules with the cornea by confocal laser scanning microscopy , 1994 .

[5]  M. Alonso,et al.  Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. , 1996, Journal of pharmaceutical sciences.

[6]  R. Smith,et al.  Tissue reactions to biodegradable and non-degradable membranes placed transcutaneously in rats, observed longitudinally over a period of 4 weeks. , 1996, Journal of oral rehabilitation.

[7]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[8]  L. Delattre,et al.  Preparation of poly(D,L-lactide) nanoparticles assisted by amphiphilic poly(methyl methacrylate-co-methacrylic acid) copolymers , 2001, Journal of biomaterials science. Polymer edition.

[9]  R. Gurny,et al.  Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. , 1998, Advanced drug delivery reviews.

[10]  Y. Ikada,et al.  In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. , 1994, Current eye research.

[11]  Y Li,et al.  PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[12]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[13]  S. Perren,et al.  Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). , 1993, Journal of biomedical materials research.

[14]  M. Martin-Iverson,et al.  Does locomotor response to novelty in rats predict susceptibility to develop sensitization to cocaine and PHNO? , 2000, Behavioural pharmacology.

[15]  R. Gurny,et al.  Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles. , 2001, International journal of pharmaceutics.

[16]  R. Levy,et al.  Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles , 2000, Gene Therapy.

[17]  J. Pastor,et al.  Polyester Nanocapsules as New Topical Ocular Delivery Systems for Cyclosporin A , 1996, Pharmaceutical Research.

[18]  David J Brayden,et al.  Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  Y. Ogura,et al.  Effect of Particle Size of Polymeric Nanospheres on Intravitreal Kinetics , 2000, Ophthalmic Research.

[20]  A. Coombes,et al.  The preparation of sub-200 nm poly(lactide-co-glycolide) microspheres for site-specific drug delivery , 1993 .

[21]  Y. Ogura,et al.  Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. , 1995, Survey of ophthalmology.

[22]  S. Gogolewski,et al.  Effect of in vivo and in vitro degradation on molecular and mechanical properties of various low-molecular-weight polylactides. , 1997, Journal of biomedical materials research.

[23]  Suming Li,et al.  Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. , 1995, Biomaterials.